secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0001213900-24-091170
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio to host Nov 7 webinar on EMACC cognitive tool for Alzheimer's trials
-------------------------------------------------------------------------------

- Webinar on Nov 7, 2024 at 1 PM ET, titled "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials."
- Poster on EMACC sensitivity and performance in Phase II Alzheimer's trial presented at CTAD2024.
- Company is conducting a Phase II trial of XPro in early AD using EMACC and CDR-SB as endpoints.
- No financial results, clinical data readouts, or material business changes disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024091170/0001213900-24-091170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024091170/ea0218711-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-091170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer